CL2011003354A1 - Proteina de union a antigeno aislada que comprende al menos un primer dominio variable de imnunoglobulina capaz de unirse a adamts5 humana; polinucleotido aislado que la codifica; celula huesped; composicion farmaceutica; y su uso para tratar enfermedades del cartilago. - Google Patents

Proteina de union a antigeno aislada que comprende al menos un primer dominio variable de imnunoglobulina capaz de unirse a adamts5 humana; polinucleotido aislado que la codifica; celula huesped; composicion farmaceutica; y su uso para tratar enfermedades del cartilago.

Info

Publication number
CL2011003354A1
CL2011003354A1 CL2011003354A CL2011003354A CL2011003354A1 CL 2011003354 A1 CL2011003354 A1 CL 2011003354A1 CL 2011003354 A CL2011003354 A CL 2011003354A CL 2011003354 A CL2011003354 A CL 2011003354A CL 2011003354 A1 CL2011003354 A1 CL 2011003354A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
host cell
variable domain
polynucleotide encoding
binding
Prior art date
Application number
CL2011003354A
Other languages
English (en)
Inventor
Michael Neil Burden
Paul Andrew Hamblin
Jonatahn David Larkin
John Richard White
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2011003354A1 publication Critical patent/CL2011003354A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)

Abstract

Proteína de unión a antígeno aislada que comprende al menos un primer dominio variable de imnunoglobulina capaz de unirse a ADAMTS5 humana; polinucleótido aislado que la codifica; célula huésped; composición farmacéutica; y su uso para tratar enfermedades del cartílago.
CL2011003354A 2009-07-02 2011-12-29 Proteina de union a antigeno aislada que comprende al menos un primer dominio variable de imnunoglobulina capaz de unirse a adamts5 humana; polinucleotido aislado que la codifica; celula huesped; composicion farmaceutica; y su uso para tratar enfermedades del cartilago. CL2011003354A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22252109P 2009-07-02 2009-07-02
US24975709P 2009-10-08 2009-10-08
PCT/US2010/040724 WO2011002968A2 (en) 2009-07-02 2010-07-01 Polypeptides and method of treatment

Publications (1)

Publication Number Publication Date
CL2011003354A1 true CL2011003354A1 (es) 2012-07-20

Family

ID=43411744

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011003354A CL2011003354A1 (es) 2009-07-02 2011-12-29 Proteina de union a antigeno aislada que comprende al menos un primer dominio variable de imnunoglobulina capaz de unirse a adamts5 humana; polinucleotido aislado que la codifica; celula huesped; composicion farmaceutica; y su uso para tratar enfermedades del cartilago.

Country Status (21)

Country Link
US (1) US20120095193A1 (es)
EP (1) EP2449127A4 (es)
JP (1) JP2012531902A (es)
KR (1) KR20120098587A (es)
CN (1) CN102482700A (es)
AR (1) AR077630A1 (es)
AU (1) AU2010266272A1 (es)
BR (1) BR112012000025A2 (es)
CA (1) CA2766641A1 (es)
CL (1) CL2011003354A1 (es)
CO (1) CO6480976A2 (es)
CR (1) CR20120027A (es)
DO (1) DOP2011000404A (es)
IL (1) IL217292A0 (es)
MA (1) MA33387B1 (es)
MX (1) MX2012000055A (es)
PE (1) PE20120554A1 (es)
SG (1) SG177288A1 (es)
TW (1) TW201114436A (es)
UY (1) UY32752A (es)
WO (1) WO2011002968A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
WO2012116260A1 (en) * 2011-02-24 2012-08-30 Glaxo Group Limited Methods of identifying a patient population
WO2013109829A1 (en) * 2012-01-20 2013-07-25 Glaxosmithkline Intellectual Property Development Ltd Anti-adamts4 antibodies and methods of treatment
PL2650310T3 (pl) * 2012-04-13 2017-01-31 Rottapharm Biotech S.R.L. Przeciwciało przeciw-ADAMTS-5, jego pochodne i zastosowania
RS65724B1 (sr) 2013-10-15 2024-08-30 Genefrontier Corp Humano antitelo protiv adamts vrste tipa agrekanaze za terapeutike bolesti povezanih sa agrekanazom
EP3328427B1 (en) * 2015-07-27 2024-05-29 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
MX2019014504A (es) * 2017-06-02 2020-07-20 Merck Patent Gmbh Inmunoglobulinas de union a agrecano.
CN110997001A (zh) 2017-06-02 2020-04-10 默克专利股份有限公司 Mmp13结合免疫球蛋白
MX2019014397A (es) 2017-06-02 2020-02-10 Merck Patent Gmbh Polipeptidos que enlazan adamts5, mmp13 y agrecano.
CN111032695B (zh) 2017-06-02 2024-06-25 默克专利股份有限公司 结合adamts的免疫球蛋白
AU2018363996B2 (en) * 2017-11-09 2024-11-07 Ribomic Inc. Aptamer for ADAMTS5, and use for aptamer for ADAMTS5
CN110760483B (zh) * 2019-11-08 2021-06-22 扬州大学 具牛、羊交叉反应的抗TNF-α单克隆抗体的制备及应用
WO2021154534A1 (en) * 2020-01-28 2021-08-05 Promab Biotechnologies, Inc. Plap-cd3 epsilon bispecific antibodies
EP4583904A1 (en) * 2022-09-07 2025-07-16 Synoa Therapeutics, LLC Methods and compositions comprising novel bispecific antibodies
CN119775410B (zh) * 2025-03-11 2025-04-29 成都大熊猫繁育研究基地 一种抗大熊猫vegfa单克隆抗体、杂交瘤细胞株及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391610B1 (en) * 1999-08-06 2002-05-21 The Cleveland Clinic Foundation Nucleic acids encoding zinc metalloproteases
EP1689716A1 (en) * 2003-12-04 2006-08-16 Wyeth Biaryl sulfonamides and methods for using same

Also Published As

Publication number Publication date
WO2011002968A3 (en) 2011-04-07
EP2449127A2 (en) 2012-05-09
JP2012531902A (ja) 2012-12-13
BR112012000025A2 (pt) 2015-09-08
CO6480976A2 (es) 2012-07-16
KR20120098587A (ko) 2012-09-05
EP2449127A4 (en) 2013-01-16
AR077630A1 (es) 2011-09-14
CA2766641A1 (en) 2011-01-06
SG177288A1 (en) 2012-02-28
MX2012000055A (es) 2012-01-27
US20120095193A1 (en) 2012-04-19
CN102482700A (zh) 2012-05-30
AU2010266272A1 (en) 2012-01-19
DOP2011000404A (es) 2012-04-15
UY32752A (es) 2011-01-31
IL217292A0 (en) 2012-02-29
MA33387B1 (fr) 2012-06-01
PE20120554A1 (es) 2012-06-08
CR20120027A (es) 2012-05-16
TW201114436A (en) 2011-05-01
WO2011002968A2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
CL2011002482A1 (es) Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
CL2011002003A1 (es) Anticuerpo humanizado o fragmentos de este, que se unen al receptor del factor de crecimiento epidérmico (egfr) en una expresión aberrante o al egfr truncado ?2-7; célula huésped; composición farmacéutica que lo comprende; y su uso para tratar tratar cáncer.
CL2008002444A1 (es) Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
AR076655A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
BR112018071307A2 (pt) anticorpos agonistas que ligam cd40 humana e usos dos mesmos
CL2011002129A1 (es) Proteinas de union a il-17; construccion de proteina de union a il-17 que comprende un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de proteina de union a il-17; vector y celula huesped; composicion para la liberacion de una proteina de union; metodo para reducir la actividad de la il-17.
CL2014000590A1 (es) Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia.
NI201700012A (es) Inhibidores de la proteina quinasa c y métodos de su uso
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
BR112012009854A2 (pt) proteína de ligação de antígeno il-23 humana
EA201270662A1 (ru) Связывающие элементы для человеческого цитамегаловируса
EA201690503A1 (ru) Антитела
CL2012001141A1 (es) Anticuerpo aislado o fragmento de este que se une específicamente a interleuquina-17a (il-17a) humana.
EA201171494A1 (ru) Миметики белка smac
EA201171374A1 (ru) Антитела против cd100 и способы их применения
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
UA103916C2 (xx) Антитіло проти dkk-1$антитело против dkk-1
EA201492149A1 (ru) St2-антигенсвязывающие белки
EA201270228A1 (ru) Полноценные человеческие антитела к btla
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
MX384191B (es) Molecula de union al antigeno especifico para el tejido objetivo.
ECSP12011885A (es) Inmunoglobulinas con dominio variable dual
EA201391457A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
CR20110152A (es) Anticuerpos anti-il-13 modificados, composiciones, métodos y usos
AR069393A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo